RENEW
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 225 patients (estimated)
- Sponsors
- Keros Therapeutics, Inc., Keros Therapeutics, Inc.
- Collaborators
- PSI CRO
- Tags
- Activin Receptor IIA Inhibitor, Closed Label (Masked), Placebo, Randomization
- Trial Type
- Treatment
- Last Update
- 1 day ago
- SparkCures ID
- 2037
- NCT Identifier
- NCT06499285
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.